Uncategorized
Treat-and-extend comparable to monthly injections in AMD
A multicenter 12-month phase 3b study showed that treat-and-extend administration of ranibizumab is “statistically noninferior and clinically comparable” with monthly treatment in patients with neovascular age-related macular degeneration.The TREND study recruited 650 treatment-naïve patients with active choroidal neovascularization secondary to AMD in 90 centers across 18 countries, randomly assigned to treat-and-extend or monthly ranibizumab 0.5 mg.